

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

# Clinical, immune and genetic risk factors of malaria-associated acute kidney injury in Zambian Children: A study protocol

Chisambo Mwaba<sup>a,b,\*¶</sup>, Sody Munsaka<sup>c</sup> & David Mwakazanga<sup>d,&</sup>, David Rutagwerae,<sup>e</sup> & Owen Ngalamika<sup>f</sup>, & , Suzanna Mwanza<sup>g</sup>, & Mignon McCulloch<sup>h</sup>, & Evans Mpabalwani<sup>a,b</sup>, &

## Author Affiliations:

- a. Department of Paediatrics and Child Health, School of Medicine, University of Zambia. P.O. Box 50110, Lusaka, Zambia.
- b. Department of Paediatrics, University Teaching Hospitals- Children’s Hospital. Lusaka, Zambia. Private Bag RW1X, Nationalist Road. Lusaka, Zambia.
- c. Department of Biomedical Sciences, School of Health Sciences, University of Zambia. P O Box 50110, Lusaka, Zambia
- d. Public Health Department , Epidemiology and Statistics Unit, Tropical Diseases Research Centre, P. O. Box 71769, Ndola, Zambia.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 e. Kaposi’s Sarcoma Molecular Laboratory, Paediatric Centre of Excellence,  
25 University Teaching Hospitals- Children’s Hospital
- 26 f. Dermatology and Venereology Division, Department of Internal Medicine,  
27 University Teaching Hospital, University of Zambia School of Medicine, Lusaka,  
28 Zambia.
- 29 g. Department of Paediatrics and Child Health, Chipata Central Hospital, Chipata,  
30 Zambia.
- 31 h. Division of Paediatric Nephrology, Red Cross War Memorial Children’s Hospital,  
32 University of Cape Town, Rondebosch 7700. Cape Town, South Africa.

33

34

35 \* Corresponding Author

36 Chisambo Mwaba, Department of Paediatrics and Child Health, University of Zambia School  
37 of Medicine, P.O. Box 50110, Lusaka, Zambia. [chisambo.mwaba@unza.zm](mailto:chisambo.mwaba@unza.zm)

38

39

40 ¶ These authors contributed equally to the work.

41 & These authors also contributed equally to the work.

42

## 43 Funding

44 C.M received a PHD scholarship from the Ministry of Technology and Science of Zambia.

45

## 46 **Competing Interests**

47 The authors have no competing interests to declare.

48

## 49 **Data Availability**

50 All relevant data has been presented in the manuscript and its associated files.

51

## 52 **Abstract**

### 53 **Background**

54 Acute kidney injury (AKI) affects nearly half of children with severe malaria and increases the  
55 risk of adverse outcomes such as death and poor cognitive function. The pathogenesis and  
56 predictors of malaria- associated acute kidney injury (MAKI) are not fully described. This  
57 study aims to determine the clinical, immune, and genetic correlates of risk to AKI in Zambian  
58 children admitted with malaria. In addition, we intend to assess a modified renal angina index  
59 (mRAI), kidney injury molecule – 1 (KIM-1), neutrophil gelatinase-associated lipocalin  
60 (NGAL)) and soluble urokinase receptor (suPAR), when done on the first day of admission,  
61 for ability to predict AKI 48 hours later (day 3) in children admitted with malaria.

### 62 **Methods**

63 This is an unmatched case-control study, with a case to control ratio of 1:1, in which 380  
64 children with malaria and aged less than 16 years are being recruited from two hospitals in

65 Zambia. Eligible children are recruited after obtaining written informed consent. Recruitment  
66 began 6<sup>th</sup> March,2024 and will continue until July 2025. AKI is defined using the 2012 KIDGO  
67 AKI creatinine criteria and cases are defined as children admitted with malaria who develop  
68 AKI within 72 hours of admission while controls are children admitted with malaria but with  
69 no AKI. Serum creatinine is collected on day 1 within 24hours of admission and then again on  
70 Day 3 post admission. Baseline biomarker concentrations will be determined using the  
71 Luminex multiplex Elisa system or high-sensitivity ELISA. SPSS version 29 will be used for  
72 data analysis. Descriptive statistics and inferential statistical tests will be run as appropriate. A  
73  $p \leq 0.05$  will be considered as significant. The utility of the renal angina score for predicting  
74 MAKI will be assessed using sensitivity, specificity, and estimates of the area under the curve  
75 (AUC).

76

77

78

## 79 **Keywords**

80 Acute kidney injury (AKI); Risk factors; AKI risk prediction; Malaria-associated acute kidney  
81 injury (MAKI); Endothelial activation; Children; Oxidative stress; Renal Angina Index;  
82 Zambia.

83

## 84 **1.0 Introduction**

### 85 **1.1 Background**

86 Worldwide, malaria is still responsible for nearly a quarter of a million under-five deaths  
87 annually and although Zambia contributes a mere 1% to total worldwide cases, malaria is the  
88 leading cause of mortality in the country. [1, 2, 3] Many of these deaths are attributable to the  
89 development of organ dysfunction including acute kidney injury (AKI). AKI which manifests  
90 in approximately 10-50% of children with malaria, increases the risk of mortality sixfold, and  
91 its long-term adverse effects include impaired cognitive function and chronic kidney disease  
92 (CKD).[4, 5, 6, 7, 8] At Lusaka's University Teaching Hospitals-Children's Hospital (UTH-  
93 CH), malaria stands as the predominant cause (60%) of AKI in children undergoing dialysis,  
94 with nearly 20% of these cases progressing to CKD.[9] The development of CKD and end-  
95 stage kidney disease (ESKD) in these patients, is life-limiting due to constraints in access to  
96 kidney replacement therapy and transplantation.[10] Yet despite this state of affairs, the  
97 epidemiology, immune and genetic risk factors of MAKI are incompletely described in our  
98 population.

99 In MAKI, risk factors may be classified as clinical or biological-various biological molecules  
100 involved in mechanisms such as cytoadherence, immune dysregulation, heme nephrotoxicity  
101 and increased oxidative stress that are involved in MAKI pathogenesis.[6, 7, 11, 12, 13] The  
102 importance of any particular risk factor in any given population may be modulated by  
103 peculiarities in local medical practice, access to healthcare resources, social determinants of  
104 health, changing malaria transmission intensity patterns and the effect of genetic variability on  
105 the function of the various immune molecules that are involved in MAKI pathogenesis.

106 Children with malaria are at increased risk of dehydration because they often present with  
107 excessive fluid losses resulting from diarrhea, vomiting, increased insensible water losses and  
108 reduced ability to ingest fluids due to poor appetite, nausea, or decreased levels of  
109 consciousness that may accompany the illness. Conroy et al found that a urea/creatinine ratio  
110 consistent with pre-renal AKI was prevalent in children with MAKI.[14] Other investigators

111 have reported comparable findings with the presence of shock being more likely in children  
112 with MAKI [15] The effect of fluid losses on the kidney may be further worsened by limited  
113 access to appropriate level of health care, cultural practices such as seeking out traditional  
114 treatments prior to presentation and use of nephrotoxins such as herbal medications and  
115 aminoglycosides. [15,16]

116 Another potential biological nephrotoxin is the oxidant, cell free haemoglobin. [4, 13, 17, 18]  
117 Elphinstone et al showed that the haem/hemopexin ratio was higher in paediatric malaria  
118 patients with stage 3 AKI compared to those without.[19] Similarly increased serum markers  
119 of hemolysis (bilirubin, lactate dehydrogenase) have been shown to correlate to greater odds  
120 of MAKI.[15] This is of particular concern in patient populations who may already have  
121 excessive intravascular haemolysis from underlying hemolytic genetic defects or indeed  
122 malaria patients with an increased parasite load (pfHRP2) who are at risk of greater haemolysis.

123 It is thought that vascular obstruction resulting from red cell sequestration in the renal  
124 circulation contributes to compromised microvascular perfusion which in turn may contribute  
125 to MAKI pathogenesis.[6,13] *Plasmodium falciparum* generates a cell-surface molecule  
126 known as PfEMP1, which facilitates the adhesion of infected red cells to endothelial cells in a  
127 process known as sequestration.[20,21] Various studies have shown a link between heightened  
128 sequestration and parasite load to higher risk of MAKI. Indirect evidence includes a correlation  
129 between markers of heightened sequestration such as *Plasmodium falciparum* histidine-rich  
130 protein 2 (*PfHRP2*) and MAKI, while more direct evidence has been drawn from a few human  
131 autopsy studies and experimental animal models.[15, 22, 23, 24] Additionally, cytoadherence  
132 leads to endothelial activation which in turn leads to worsening cytoadherence which results  
133 into a vicious cycle in which worsening cytoadherence begets endothelial activation and vis  
134 versa.[11, 13, 25] Some studies have found that increased markers of endothelial activation,

135 increased circulating soluble cell adhesion molecules as well as increased monocyte activation  
136 are linked to greater risk of organ dysfunction including MAKI .[26, 27, 28, 29, 30]

137 Furthermore, polymorphisms in the genes coding for these various immune molecules may  
138 influence gene function with resultant alteration in amounts or function of the gene  
139 products.[31, 32] Numerous studies have suggested a link between immune molecule gene  
140 polymorphisms with various severe malaria syndromes.[33, 34, 35, 36] However, most of  
141 these studies lacked statistical power to detect associations with MAKI due to heterogeneous  
142 samples encompassing various forms of severe malaria.

143 There is limited data evaluating the utility of these various immune molecules, or indeed the  
144 numerous emerging AKI biomarkers such as kidney injury molecule – 1 (KIM-1), neutrophil  
145 gelatinase-associated lipocalin (NGAL) and soluble urokinase receptor (suPAR), in prediction  
146 of MAKI.[37, 38] Additionally, although some clinical prediction rules such as the Renal  
147 Angina Index (RAI) have been formulated, these have mostly been tested in general paediatric  
148 intensive care unit (PICU) populations and have not been validated in children with  
149 malaria.[39] RAI utilizes risk factors for AKI and early clinical signs of kidney injury to create  
150 a composite score with a score greater than 8 out of 40 being predictive of increased AKI  
151 risk.[39]

152 We hypothesize that various clinical factors, serum concentration of immunological molecules,  
153 as well as genetic polymorphisms of selected immune factors are correlated to the risk of  
154 developing AKI in children admitted with malaria and can therefore be used for risk prediction  
155 in MAKI. Specifically, we hypothesize that 1)delayed access to care, hyperparasitaemia,  
156 increased oxidative stress, presence of exaggerated haemolysis and dehydration increase the  
157 risk of MAKI, 2) that MAKI is associated with higher concentrations cytokines or serum  
158 markers of endothelial activation, 3) that the Renal Angina Index, NGAL, suPAR and KIM-1

159 when used in severe malaria may be useful in predicting severe AKI at 48 hours and 4) that  
160 ten (10) immune molecule single nucleotide gene polymorphisms (SNPs) are associated with  
161 an altered risk of AKI in children admitted for malaria.

162 The purpose of this study is to 1) to determine the correlation between clinical risk factors  
163 (hyperparasitaemia, delayed access to care, urea/creatinine ratio > 20, increased oxidative  
164 stress, increased serum bilirubin and low haemoglobin) and MAKI, 2) determine the  
165 correlation between plasma pro- and anti-inflammatory cytokine concentrations and MAKI, 3)  
166 to assess the relationship between ten (10) immune molecule gene polymorphisms namely  
167 interleukin (IL)-10 (rs1800871, rs1800871), tumor necrosis factor-alpha (TNF- $\alpha$ ) (rs361525,  
168 rs1800629), Type I Interferon alpha receptor 1 (IFNAR1) (rs2843710, rs2243594), haem-  
169 oxygenase-1(HMOX1) (rs7285877), nitric oxide synthetase 2(NOS2), Transforming growth  
170 factor beta-2 (TGF-Beta 2) (rs4846478) and toll-like receptor- 4(TLR4) (rs4986791) and the  
171 MAKI phenotype, 4) to determine the utility of the Renal Angina Score in predicting MAKI  
172 and assess whether its modification with population specific predictors will lead to enhanced  
173 performance and finally, 5) to determine the predictive value of novel biomarkers (NGAL,  
174 suPAR, KIM-1) in MAKI. We hope that the proposed work will provide evidence that will  
175 improve early diagnosis of MAKI and consequently result into adoption of protocols that  
176 promote the institution of remedial treatments and referral of children in a timelier manner.

177

## 178 **2.0 Materials and methods**


### 179 **2.1 Study design**

180 The project is divided into two sub-studies namely 1) Sub-study 1 which answers objectives 1,  
181 2 and 3, and is an unmatched case-control study with a case: control ratio of 1:1. An unmatched



182 design was chosen because this is an exploratory study however during analysis of data for the  
183 immune molecules patients will be analysed based of age groups. Sub-study 2 answers  
184 objectives 4 and 5 and is a nested prospective observational study that recruits participants  
185 from the control arm of sub-study 1 (Fig1).

186



187

188 **Fig 1: Study design and recruitment plan**

189 This is a case-control study with a nested prospective observational study. Participant serum creatinine will be  
190 determined on Day 1 and on Day 3. Patients meeting KDIGO AKI creatinine criteria will be classified as cases  
191 while those who do not meet the KDIGO creatinine AKI criteria will be classified as controls. The nested  
192 prospective observational study draws its study population from the cohort of malaria patients with absent AKI  
193 on day 1. serum creatinine will be repeated on day 3 in order to determine if KDIGO stage 2/3 (severe) AKI will  
194 have developed on Day 3.

195

## 196 **2.2 Study setting**

197 The study participants are drawn from Chipata Central Hospital (CCH) in Chipata town of the  
198 Eastern province of Zambia and from the University Teaching Hospitals Children's Hospital  
199 (UTHs-CH) in the capital city of Zambia, Lusaka.

200 Chipata town is located about 600 km from Lusaka and is the provincial capital of the Eastern  
201 province which is a medium malaria transmission zone (parasite prevalence among children in  
202 Eastern Province is 21%).(40) Most cases of malaria occur in the first six months of the year  
203 (seasonal transmission).(40) CCH is a tertiary hospital with the four major specialties of  
204 paediatrics, internal medicine, surgery and obstetrics and gynecology available. The hospital  
205 has a capacity of 500 beds and is an internship-training site and fellowship-training site for all  
206 the above-mentioned specialties. The paediatrics department has a capacity of 70 beds with  
207 access to level II intensive care unit (ICU) that admits neonates, children and adults with both  
208 medical and surgical conditions The paediatrics department has a capacity of 70 beds with  
209 access to level II mixed intensive care unit (ICU). The selection of this site was based on a  
210 prior study conducted at UTH, revealing that CCH ranked as the second most frequent hospital  
211 referring children with MAKI for treatment at UTHs-CH, nephrology unit. Additionally, the  
212 chosen site provides robust support for the study. The site has good laboratory support  
213 including the presence of an ultra-low freezer (-80°C) and capacity to conduct PCR.

214 The UTH-CH is the leading tertiary paediatric hospital in Zambia, located in Lusaka district,  
215 which is a very low Malaria transmission zone.[40] The hospital receives referrals from across  
216 the country and has the older and larger of the two pediatric dialysis centers in the country. The  
217 hospital has a capacity of 350 beds. The nephrology unit evaluates about 300 children per year  
218 and a third of these have AKI. The site was chosen to capture the more severe forms of MAKI  
219 that tend to be referred from across the country. The site has access to molecular laboratories  
220 including Kaposi's Sarcoma (KS) molecular laboratory with subzero freezers, PCR machines,  
221 sequencers, flow cytometer, facilities for gel electrophoresis and staff trained in these  
222 techniques.

223

## 224 **2.3 Study population**

225 Children aged less than 16 years who are admitted for malaria (modified CDC 2014 definition)  
226 at the UTHs-CH and CCH constitute the target population. Recruitment began 6<sup>th</sup> March,2024  
227 and will continue until July 2025. For sub-study 2, the nested prospective observational study,  
228 the study population is drawn from the cohort of malaria patients with no AKI on day 1 (Fig 1).

229

## 230 **2.3 Inclusion and exclusion criteria**

231 To be included in the study a child has to be between 6 months and 16 years old, have  
232 parasitological evidence of malaria and be admitted to either UTHs-CH or CCH. The upper  
233 age limit for admission to the pediatric services at the two hospitals is 16 years.

234 Children who are known to have CKD and children who have received dialysis prior to  
235 admission for the episode of AKI are excluded. Dialyzed patients are excluded because serum  
236 levels of various biomarkers may be distorted during dialysis.

237

## 238 **2.4 Study definitions**

239 Any child with history of fever exhibiting signs or symptoms consistent with malaria (fever,  
240 chills and sweats, headaches, muscle pains, nausea, vomiting, fatigue, anemia, coma, seizures,  
241 focal neurological signs, respiratory distress) who shows evidence of plasmodium infection by  
242 a)Detection of malaria by rapid diagnostic antigen (RDT) testing without confirmation by  
243 microscopy or nucleic acid testing e.g., in this study.[41] OR b) Detection of parasites by  
244 microscopy on blood films will be defined as having malaria.

245 In areas of high malaria endemicity a positive slide, RDT or even presence of positive nucleic  
246 acid test does not definitively prove that a patient has clinical malaria as many children may  
247 have asymptomatic infection along with other conditions that could explain the clinical  
248 presentation.[42, 43]

249 A child aged 6 months to 16 years old who meets the KIDGO 2012 AKI criteria and who has  
250 malaria as per the modified CDC malaria case definition is categorized as having MAKI. A  
251 case is a child 6 months old to 16 years of age with MAKI detected within the first three days  
252 of admission while a control is defined as a child aged 6 months to 16 years of age with malaria  
253 but with NO MAKI within the first three days of admission.

254

## 255 **2.5 Sample size estimation and sampling methods**

256 The study plan is to recruit a total of 380 patients, with 190 being case while 190 will be  
257 controls. A rate of 10% for missing data is factored in. This sample size will provide 80%  
258 power, with a statistical significance of 5%, to detect an effect sizes equivalent to those reported  
259 in previous studies. [14, 15, 44, 45, 46, 47, 48, 49, 50, 51, 52] Supplementary information (S1

260 **effect sizes and estimation of sample size)** provides details for both sub-study 1 and sub-study  
261 2. This is an exploratory study therefore no matching of cases to controls will be conducted at  
262 recruitment. However, during laboratory analysis of the various immune molecules 100 cases  
263 will be matched to 100 controls based on age groups (less than 5 years, 5-10 years and greater  
264 than 10 years) with 20 children assigned to each age group for both cases and controls, in order  
265 to account for the well-known effect of age on immune molecule serum concentrations.  
266 Consecutive sampling is being used.

267

## 268 **2.6 Sub-study 1**

### 269 **2.6.1 Sub-study 1 Recruitment Procedure**

270 Screening of children with malaria is conducted by the study nurse. The purpose of the study  
271 is explained to the legal guardians or parents of all potential participants. Written informed  
272 consent and assent (children > 8 years if fully conscious) where appropriate, is obtained after  
273 explaining the purpose of the study to potential participants. The Information sheet, consent,  
274 and assent forms are available in the predominant languages of these regions, namely English,  
275 Bemba, Nyanja, and Tonga, and are administered according to the preferred language of  
276 communication chosen by potential participants. Each participant is then assigned a unique  
277 study number. A pre-designed data collection form on Redcap TM is used to collect participant  
278 demographic and clinical data.

279 Children are recruited from both study sites. The recruitment procedure is illustrated in Fig 1.  
280 The Case definition of MAKI is development of AKI (KDIGO 2012 criteria) within the first  
281 three days of admission. The patient's creatinine is collected at recruitment (Day 1, within the  
282 first 24 hours of admission) as well as on Day 3 of admission. Malaria patients meeting  
283 definition of MAKI based on creatinine result collected at recruitment on day 1 or on day 3 are

284 assigned into the case arm of the study. Malaria patients who do not meet definition of MAKI  
285 based on serum creatinine result from samples collected on day 1 and on day 3 are assigned  
286 into the control arm of the study. Additionally, all children referred to the study site with a  
287 diagnosis of MAKI already made are also recruited as cases after confirmation of blood results  
288 at the study site.

289 Specimens for serum urea, bilirubin, potassium, sodium, haemoglobin, and platelet count are  
290 also collected. Finally, also being collected at baseline are specimens for kidney biomarkers,  
291 cytokines, adhesion molecules, pfHRP2 and malondialdehyde (MDA).

292 Venous blood aliquot, which is computed based on the child's age and weight, is drawn,  
293 ensuring that the amount for any single blood draw does not exceed the maximum allowable  
294 volume, set at 2.5% of the total blood volume, following widely used guidelines for both  
295 clinical and research purposes.[53] The collected whole blood is placed in heparinized  
296 vacutainer, 2 EDTA vacutainer and in a plain tube. The specimen in the plain tube vacutainer  
297 will be left at room temperature for 10 minutes to facilitate clot formation. Subsequently, this  
298 sample undergoes centrifugation at 3000 rpm for at for 5 minutes, after which the supernatant  
299 is stored at -80°C. The sample in the heparinized container similarly undergoes centrifugation  
300 at 3000 rpm for 5 minutes. The supernatant is also stored in a cryovial and stored at -80<sup>0</sup> C for  
301 onward transport and processing at UTH-CH.

302

### 303 **2.6.2 Sub-study 1 Laboratory procedure**

304 All the specimens kept at -80<sup>0</sup> C are transported to the UTH-CH on dry ice for analysis. The  
305 Beckman Coulter AU 480 analyser will be employed to assess blood parameters, including  
306 creatinine, sodium, potassium, bilirubin and urea as per manufacturer instructions. Blood

307 platelet count and haemoglobin are determined at each respective study site using the Sysmex  
308 XT 4000i haematology analyser.

309 To conduct the cytokine analysis the frozen serum will be thawed. A Bead based multiplex  
310 assay (cytometric bead array) will be done on a Luminex™ platform, at the KS molecular  
311 laboratory, at UTH-CH, will be used to analyze the serum cytokine concentrations. The  
312 manufacturer's protocol will be followed to run the assay.

313 A calibration curve for calculating the concentration of cytokines will be created using the  
314 manufacturer's provided lyophilized standards in the kits, and the cytokine concentrations in  
315 samples will then be deduced from standard curves. Because immunoassays generate a  
316 sigmoid-shaped curve, logistic regression mathematical modelling is used to allow curve fitting  
317 beyond the linear range of the curve. This facilitates subsequent determination of the Y-  
318 intercept and gradient. The lower limit of detection for the various cytokines will be  
319 determined. If readings are above the upper limit of detection, dilutions of 1:4, 1:8, 1:16 and  
320 so on will be done until a negative result, then the dilution factor will be used to determine the  
321 actual concentration.[49]

322 For quantification of oxidative stress, the MDA NWLSSTM malondialdehyde assay will be  
323 used. All the laboratory analytes in this study are shown in **Table 1**.

324

325 **Table 1: Study analytes**

<b>Biomarker</b>	<b>Specimen</b>	<b>Test</b>
<b>Interleukin 18</b> <b>Interleukin 1</b> <b>Interleukin 10</b> <b>Interleukin 6</b> <b>Interleukin 12</b> <b>Soluble TNF-<math>\alpha</math></b> <b>IFN-<math>\gamma</math></b>	Plasma	Cytometric bead array
<b>Angiopietin 1</b>	Plasma	Cytometric bead array

<b>Angiopietin 2 Endothelial cell protein C receptor (EPCR). ICAM-1, VCAM</b>			
<b>MDA</b>	Plasma	MDA NWLSSTM (commercial oxidative stress kits)	malondialdehyde assay
<b>pfHRP2</b>	Blood	ELISA	

326

327 Twelve polymorphic markers are proposed for investigation in this study. They have been  
 328 chosen based on previous associations in the literature to other forms of severe malaria or other  
 329 AKI phenotypes with a postulated similarity in pathophysiology to MAKI.

330 Whole blood is collected onto special filter paper cards as dried blood spots for later genomic  
 331 DNA extraction.[54] Genomic DNA will be extracted using a commercial DNA purification  
 332 kit (QIAwave DNA Blood and Tissue Kit by Qiagen TM ). Polymerase Chain Reaction (PCR)  
 333 will be used for DNA amplification. We will use primers as described in previous experiments  
 334 and for those SNPs where we could not find references in the literature, we searched NCBI  
 335 gene to obtain information on the location of the target then we obtained the sequence of the  
 336 area of interest in FASTA format and used the NCBI primer tool to design appropriate primers.  
 337 The QiagenTM Multiplex PCR kit (cat no.206143) and primers (**S2 List of primer sequences**),  
 338 and restricting enzymes for the 12 gene polymorphisms will be placed in a thermal cycler as  
 339 per manufacturer protocol. Gel electrophoresis will then be conducted to determine the  
 340 presence of the SNPs of interest, then for positive samples the PCR products will be purified  
 341 using a commercial kit, before subjecting them to Sanger sequencing (ABI 3500) at the School  
 342 of Veterinary Medicine genomics laboratory, University of Zambia.

343

### 344 **2.6.3 Sub-study 1 variables**



345 The study collects information on occurrence of MAKI in admitted malaria patients as the  
346 primary outcome variable. Serum creatinine is collected at discharge or if the patient is still  
347 hospitalized on day 7 to establish the renal outcome. Renal outcome is noted as a secondary  
348 outcome. Outcome is classified as normal renal function if eGFR is  $>120\text{ml}/1.73\text{m}^2/\text{min}$  or  
349 abnormal for eGFR  $< 120\text{ml}/1.73\text{m}^2/\text{min}$ . The Schwartz formula is used to estimate GFR.

350 The three categories of independent variables for this proposed study are socio-demographic,  
351 clinical, and laboratory variables. Socio-demographic factors encompass the patient's age,  
352 gender, place of residence (village/suburb), distance from the referring facility, the referring  
353 health facility, province of origin, and self-identified ethnic group. Ethnic group data is being  
354 collected for analyzing genetic information among participants.

355 Clinical independent variables include patient height/length, weight, hydration status  
356 (classified according to WHO as none, some, and severe)[55], vital signs (blood pressure,  
357 oxygen saturation, presence of edema), and Glasgow Coma Score upon admission. Additional  
358 clinical variables being collected include the reason for referral, identification of AKI at the  
359 referring facility, date of AKI identification if applicable, history of anuria/oliguria, and pre-  
360 admission seizure history. Other clinical variables comprise duration of illness before  
361 admission, pre-admission medications and dosages, family history of renal disease, the patient's  
362 past medical history, and the number of blood transfusions in the current illness. Additionally,  
363 birth weight, Length of hospital stay, admission to and duration of admission to PICU,  
364 mortality, are documented.

365 Laboratory independent variables are the admission creatinine, admission estimated glomerular  
366 filtration rate (GFR), hemoglobin electrophoresis, admission hemoglobin, bilirubin, platelet  
367 count, and random blood sugar (RBS). Routine HIV testing is conducted for all pediatric  
368 patients upon admission, following an opt-out system for caregivers. Recorded HIV test results

369 in the patient file are documented. Further laboratory results on admission include PfhHRP2  
370 levels, cytokine levels (IL-18, IL-1, IL-10, IL- 12, Soluble TNF- $\alpha$ , IFN- $\gamma$ ), adhesion molecule  
371 levels (Ang-1, Ang-2, EPCR, ICAM-1, VCAM), and markers of oxidative stress (MDA).

372

#### 373 **2.6.4 Sub-study 1 data analysis**

374 Patient data will be analyzed utilizing IBM SPSS Statistics version 29 (IBM Corp., Armonk,  
375 NY, USA). Categorical variables will be presented as frequencies and percentages. For  
376 continuous variables, those with asymmetric distributions will be reported as medians and  
377 interquartile ranges (IQRs), while those with normal distributions will be presented as means  
378 and standard deviations (SDs). The normality of continuous data will be assessed using the  
379 Shapiro-Wilk test.

380 To assess the strength of associations between various categorical exposure variables and the  
381 outcome (AKI), the chi-square test will be employed. In cases where any cell in the contingency  
382 table contains fewer than five expected observations, the Fisher's Exact test will be used.

383 For the association of normally distributed continuous variables, the independent t-test will be  
384 applied to compare means between the two groups. Non-normally distributed continuous data  
385 will undergo non-parametric testing, such as the Mann-Whitney U test or the Kruskal-Wallis  
386 test. Multivariate logistic regression will be conducted to address potential confounding  
387 factors. All statistical tests will be two-tailed, and a significance level of  $p \leq 0.05$  will be  
388 considered statistically significant.

389 Analysis of immune molecule data will be conducted using GraphPad Prism software (Version  
390 9, San Diego, CA, USA). Cytokine data will be represented as geometric means with a 95%  
391 confidence interval (CI) to illustrate the central tendency of cytokine levels. Significant

392 differences between cases and controls will be assessed using either the t-test or the Mann-  
393 Whitney U test.

394 To evaluate the discriminatory power of each immune molecule between cases and controls, a  
395 Receiver Operator Curve (ROC) will be constructed. Multiple logistic regression analyses for  
396 each cytokine/adhesion molecule will be carried out to compare cases versus controls. The  
397 goodness of fit for the model will be assessed using the Hosmer-Lemeshow test.

398 The level of association of the various polymorphisms to MAKI will be determined. The  
399 clinical and demographic composition of the cases and controls will be compared using the  
400 Chi-square test or Fischer's Exact test. The level of correlation of the two groups to the presence  
401 of the SNPs of interest will be done using Chi-square and Fisher's exact tests. All loci will be  
402 assessed for the presence of Hardy–Weinberg equilibrium. A P-value of <0.05 will be  
403 considered statistically significant.

404

## 405 **2.7 Sub-study 2 (Nested prospective cohort study)**

### 406 **2.7.1 Sub-study 2 Recruitment Procedure**

407 This is a nested study utilizing a prospective observational study. Recruitment is conducted as  
408 shown in Fig 1. Written informed consent and assent where appropriate are obtained after  
409 explaining the purpose of the study to potential participants as described in sub-study 1.  
410 Baseline scoring of the renal angina index (**Table 2**) within the first 24 hours after admission  
411 using a pre-designed data collection form is done. Fluid overload is determined as the  
412 difference in body weight at recruitment and at admission to hospital divided by the weight at  
413 admission to hospital expressed as a percentage.[56] The patient baseline creatinine is collected  
414 at admission as described under the methods section for sub-study 1. The KDIGO 2012

415 creatinine criterion is used to define AKI and severe AKI is defined as KIDGO 2012 stage 2  
 416 and 3 AKI as per previous studies.

417

418 **Table 2: The renal angina score**

<b>RAI= Risk X Injury</b>					
<b>(score ranges from 1-40)</b>					
<b>INJURY</b>			<b>RISK FACTOR</b>		
<b>% Drop in eGFR</b>	<b>% FO</b>	<b>Score</b>		<b>Risk factor</b>	<b>Score</b>
No change	≥5%	1		PICU admission	1
0-25%	≥5%	2	<b>X</b>	Stem cell transplantation	3
25-50%	≥10%	4		Ventilation or use of vasoactive agent	5
≥0%	≥ 15%	8			

419

420 For biomarkers (KIM-1, suPAR, NGAL) 4ml of whole blood is collected (same sample as for  
 421 sub-study 1) in plain tubes left at room temperature for 10 minutes until clot formation. Later  
 422 the sample is centrifuged. The supernatant is then stored at -80 °C as described in sub-study 1.  
 423 Concentrations of AKI biomarkers (KIM-1, NGAL, suPAR) will be determined using Luminex  
 424 multiplex bead-based array or high-sensitivity ELISAs such as Quantikine® assays as outlined  
 425 for sub-study 1.

426

### 427 **2.7.2 Sub-study 2 variables**

428 Sub-study 2 primary outcome variable are the occurrence of KDIGO stage 2 or stage 3 (severe)

429 AKI on Day 3. Secondary outcome variables are Death, whether a patient required dialysis or

430 PICU admission and the length of hospital stay.

431 The sub-study 2 independent variables are the composite Day 1 RAI score, the various patient

432 baseline clinical features and the baseline (day 1) serum concentrations of NGAL, KIM-1 and

433 SuPAR.

434

### 435 **2.7.3 Sub-study 2 data analysis**

436 Data will be exported from RedCap TM to an excel spreadsheet and then imported into an IBM

437 TM-SPSS TM version 29 (IBM Corp., Armonk, NY, USA) database for data analysis in SPSS

438 version 29. Categorical data will be expressed as frequencies and percentages while continuous

439 data will be expressed as median and interquartile range if of asymmetric distribution while

440 data that has a normal distribution will be expressed as means with standard deviation (SD).

441 The Shapiro-Wilk test will be used to determine data distribution.

442 To test the association between continuous data and the outcome variable (severe AKI at Day

443 2 Yes/No), the independent t test (parametric data) or Mann-Whitney test (non-parametric data)

444 will be used. Categorical data will be tested for association to the outcome variable (severe

445 AKI Yes/No), using the Chi-square or Fisher's exact test for cells containing less than five. A

446  $p \leq 0.05$  will be considered as being statistically significant.

447 All variables showing an association to the bivariate form of the outcome variable (severe AKI

448 48hrs later Yes/No) with a probability of less than 25 % ( $p < 0.25$ ), and all independent variables

449 previously shown to have association with the outcome variable (severe AKI on day 3 of-

450 admissions Yes/No) from the literature will be used to construct a multivariate logistic

451 regression model.

452 The quality of the multivariable models will be assessed using the likelihood-ratio (LR) chi-  
453 square test on the models for the global null hypothesis that none of the added potential  
454 predictors predicts the dependent variable, the Hosmer and Lemeshow (H&L) goodness-of-fit  
455 test, and the C-statistic.

456 The utility of the renal angina score for predicting MAKI will be assessed using sensitivity,  
457 specificity, negative and positive predictive values (NPV and PPV) and estimates of the area  
458 under the curve (AUC). Local risk factors as identified from the cohort using multivariate  
459 logistic regression will be incorporated into the RAI in order to test if this will improve  
460 performance. Youden's index will be used to determine the cut-off point for the modified RAI  
461 and curve fitting techniques will be utilized as described in previous studies by Matsuura et  
462 al.[57, 58, 59] The AUC of the modified RAI and the AUC obtained from the original RAI will  
463 be compared using the z-test (non-parametric).

464

## 465 **2.8 Ethical considerations**

466 This research is being conducted in compliance with guidelines for good clinical practice and  
467 ethical standards as espoused in the Declaration of Helsinki and the International Declaration  
468 on Human Genetic Data.

469 Permissions: Ethical clearance was sought and obtained from UNZABREC (REF. No. 4269-  
470 2023) and NHRA. Further, the hospital management at CCH and UTHs-CH have granted  
471 permission to conduct the study in the two sites respectively.

472 Informed consent: The study nurse explains the purpose of the study to parents/guardians of  
473 prospective study participants in the language of the participants' choice utilizing an interpreter  
474 where necessary (the interpreter will also co-sign the consent form) and using the study

475 information sheet for guidance. The study nurse further explains that participation is voluntary  
476 and that participants would be free to withdraw at any time and without explanation if they so  
477 wish and that they will not suffer any punitive measures as a result. The parents/guardians are  
478 offered a copy of the study information sheet in a language of their choice to read through and  
479 follow along. They are also given an opportunity to seek further clarifications or ask questions  
480 and then the study nurse invites them to participate in the study.

481 If the parent guardian agrees to participate, they are asked to sign the written consent form  
482 which is available in Bemba, English, Lozi, Nyanja and Tonga. The signature is witnessed by  
483 a person of the parents' choice. The study nurse takes a picture of the signed consent form and  
484 uploads it to the study database, gives a copy to the parent/guardian and also keep a copy in a  
485 file kept at the study site in the research office at the site.

486 Assent: For children whose parent/guardian has given written informed consent, and the child  
487 is older than 7 years and able to understand the information presented and is medically able to  
488 assent they are asked to assent by the study nurse in the presence of their parent/guardian.

489 Confidentiality: the interview is conducted in a corner /room away from the main ward. Each  
490 participant is assigned a unique study number that is used with the stored data and during the  
491 laboratory processing of samples. The screen book with participant data which includes names  
492 is kept in a locked cabinet in the site research office. Once the study concludes the logbooks  
493 will be held by the overall PI at UTH-CH in a locked cabinet at UTH-CH

494 Description of Risks: there are no additional risks associated with participation in the study.  
495 Participants experience mild pain during phlebotomy. The risk of infection to injection site  
496 during phlebotomy is reduced by sterilizing the site of injection as per standard  
497 medical/hospital procedure. These procedures are all conducted by trained health workers  
498 (nurse or doctor).

499 Emergency care and insurance for research-related injuries: This is an observational study and  
500 so no interventions will be made on participants, and all procedures such as phlebotomy do not  
501 represent added risk beyond that which participants undergo during the process of receiving  
502 the standard care offered by the hospital. Thus, no insurance is offered to participants.

503 Description of Benefits and anticipated gain in scientific knowledge: There are few direct  
504 benefits to participants. At times hospitals do not have functional laboratory consumables to  
505 conduct regular blood tests but during the course of the study for all participants baseline blood  
506 results are done and made available to the attending doctor. A transport refund is also offered  
507 if collection of discharge data may delay the departure of the patient.

508 Much of the anticipated benefit is long term. Information gleaned from this work will shade  
509 light on the risks of MAKI in the local Zambian environment and may help clinicians and  
510 policy makers to formulate strategies to prevent MAKI in the future.

511 Also, if the various biomarkers evaluated prove to be able to accurately predict MAKI before  
512 it is clinically evident, they may be used to design point-of-care tests that will make diagnosis  
513 of MAKI faster and earlier and allow implementation of treatments to mitigate the effects of  
514 MAKI in children.

515

## 516 **3.0 Discussion**

### 517 **3.1 Study limitations**

518 Since the proposed study is not prospective from point of infection, the recruited patients are  
519 at different stages along the disease pathophysiology. This may influence the levels of the



520 various biomarkers that in turn may act as a confounder affecting the significance that may be  
521 attached to the determined risk factors.

522 Moreover, the significance of a specific SNPs in relation to the disease varies frequently across  
523 diverse populations and is notably influenced by ethnicity. Many of the SNPs employed in this  
524 study were originally characterized in diverse populations, which may result in a lack of  
525 association with MAKI. This might lead to a false conclusion that polymorphisms associated  
526 with these immune factors have no effect upon the severity of renal involvement in malaria.

527 It is an accepted fact that the relationship between genetic variation and expression of complex  
528 syndromes such as AKI is complex because most of the gene products work within networks  
529 in which redundancy, compensatory mechanisms and feedback mechanisms come into play.  
530 Thus, the lack of association between an SNP and AKI in an in vivo setting may just be a  
531 reflection of this fact.

532

### 533 **3.2 Data management and quality assurance**

534 Data is captured using a digital form in RedCap TM. Data will be exported to a *Microsoft Excel*  
535 version 16.0 (Microsoft Corp, Redmond, WA, USA) spreadsheet and then imported into an  
536 IBM TM-SPSS TM version 25 (IBM Corp., Armonk, NY, USA) database for storage and initial  
537 data analysis. The database will be securely stored on a password-protected computer, with  
538 access restricted to essential research team members, such as the statistician.

539 Prior to the commencement of participant recruitment, all research team members underwent  
540 training on data collection standards, conducted by the Principal Investigator (PI). Throughout  
541 the study, the PI will perform weekly reviews of all data entry forms to ensure completeness  
542 and accuracy. Any identified errors or missing data will be addressed promptly by consulting

543 the responsible research team member for correction. All team members have been briefed on  
544 the proper protocols for specimen collection, transportation, and handling.

545 Specimens designated for molecular and genetic analysis will be transported on dry ice in a  
546 cooler box from the Clinical Center Hospital (CCH) to the Kaposi's Sarcoma (KS) laboratory,  
547 where they will be stored for long-term analysis. The laboratories involved in specimen  
548 processing include the KS molecular laboratory and the University of Zambia Veterinary  
549 School genetics laboratories. Both laboratories are accredited and recognised as national  
550 reference laboratories.

551 Procedures for specimen handling and processing will adhere strictly to established standards.  
552 These standards include appropriate labeling, documentation, and storage conditions to  
553 maintain specimen integrity throughout the study.

554

### 555 **3.3 Dissemination plan**

556 Results of this study will be used to write a thesis in partial fulfilment for the award of the  
557 degree of Doctor of Philosophy (PhD) at the University of Zambia. Reports will be presented  
558 to the medical library and the university, and a soft copy will be available online. Findings will  
559 be published in peer-reviewed journals.

560

### 561 **3.4 Discarding of study materials**

562 Left over blood samples will be kept at -800 C freezer in the KS molecular laboratory at UTH-  
563 CH for five years and may be used in future studies examining complicated malaria in children  
564 if permission is granted at that time from the ethical review board for an extension of the study.

565

### 566 3.5 Projected Timeline

567 This study is projected to run from 2023 to 2026 as shown in **Table 3**.

568

569 **Table 3: Gantt chart**

Activity	2023				2024				2025				2026			
	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4
Research proposal Development	■	■														
Ethics and NHRA approvals			■	■												
Sample Collection					■	■	■	■	■	■	■					
Laboratory Analysis												■	■	■	■	
Review paper Submitted					■	■										
Paper 1 Submitted										■	■					
Paper 2 submitted												■	■	■		
Paper 3 Submitted													■	■		
Project wind down and															■	■

570 Legend: Q= Quater

571

### 572 Author contributions

573

574 **Conceptualization:** Chisambo Mwaba, Evans Mpabalwani, Sody Munsaka

575 **Writing – original draft:** Chisambo Mwaba

576 **Supervision-** Evans Mpabalwani, Sody Munsaka, Mignon McCulloch, Owen Ngalamika

577 **Writing – review & editing:** Chisambo Mwaba, Owen Ngalamika, Sody Munsaka, David  
578 Mwakazanga, David Rutawgwerae, Suzanna Mwanza, Mignon McCulloch, Evans  
579 Mpabalwani

580

## 581 **Acknowledgments**

582 We are grateful to Monica Mweetwa for reviewing the draft manuscript.

583

## 584 **References**

585 1. Cox FE. History of the discovery of the malaria parasites and their vectors. *Parasit vectors*.  
586 2010;3(1):1-9.

587 2. Who. World malaria report 2020: 20 years of global progress and challenges. World Health  
588 Organization Geneva; 2020. p. 1-151.

589 3. Health ZMo. Annual Health Statistical Report 2017-2021 (Tracking the performance of the  
590 NHSP 2017-2021. Lusaka: Government of the Republic of Zambia Ministry of Health; 2022.

591 4. Batte A, Berrens Z, Murphy K, Mufumba I, Sarangam ML, Hawkes MT, et al. Malaria-  
592 Associated Acute Kidney Injury in African Children: Prevalence, Pathophysiology, Impact,  
593 and Management Challenges. *Int J Nephrol Renovasc Dis*. 2021;14:235-53.

594 5. Tembo D, Mwanza S, Mwaba C, Dallah I, wa Somwe S, Seydel KB, et al. Risk factors for  
595 acute kidney injury at presentation among children with CNS malaria: a case control study.  
596 *Malar J*. 2022;21(1):310.

597 6. Plewes K, Turner GDH, Dondorp AM. Pathophysiology, clinical presentation, and  
598 treatment of coma and acute kidney injury complicating falciparum malaria. *Curr Opin Infect*  
599 *Dis*. 2018;31(1):69-77.

- 600 7. Das BS. Renal failure in malaria. *J Vector Borne Dis.* 2008;45(2):83-97.
- 601 8. White NJ. Severe malaria. *Malar J.* 2022;21(1):284.
- 602 9. Mwaba C, Munsaka S, Bvulani B, Mwakazanga D, Chiluba BC, Fitzwanga K, et al.  
603 Malaria is the leading cause of acute kidney injury among a Zambian paediatric renal service  
604 cohort retrospectively evaluated for aetiologies, predictors of the need for dialysis, and  
605 outcomes. *PLoS One.* 2023;18(10):e0293037.
- 606 10. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal  
607 disease and use of therapy. *PLoS One.* 2013;8(8):e72860.
- 608 11. Mariana Conceição de S, Tatiana Almeida P, Maria das Graças H. Multiple Organ  
609 Dysfunction During Severe Malaria: The Role of the Inflammatory Response. In: Alfonso  
610 JR-M, editor. *Current Topics in Malaria.* Rijeka: IntechOpen; 2016. p. Ch. 5.
- 611 12. Barsoum RS. Malarial acute renal failure. *J Am Soc Nephrol.* 2000;11(11):2147-54.
- 612 13. Katsoulis O, Georgiadou A, Cunnington AJ. Immunopathology of Acute Kidney Injury in  
613 Severe Malaria. *Front Immunol.* 2021;12.
- 614 14. Conroy AL, Hawkes M, Elphinstone RE, Morgan C, Hermann L, Barker KR, et al. Acute  
615 Kidney Injury Is Common in Pediatric Severe Malaria and Is Associated With Increased  
616 Mortality. *Open Forum Infect Dis.* 2016;3(2).
- 617 15. Namazzi R, Batte A, Opoka RO, Bangirana P, Schwaderer AL, Berrens Z, et al. Acute  
618 kidney injury, persistent kidney disease, and post-discharge morbidity and mortality in severe  
619 malaria in children: A prospective cohort study. *EClinicalMedicine.* 2022;44:101292.
- 620 16. Mousa A, Al-Taiar A, Anstey NM, Badaut C, Barber BE, Bassat Q, et al. The impact of  
621 delayed treatment of uncomplicated *P. falciparum* malaria on progression to severe malaria: A

- 622 systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Med.  
623 2020;17(10):e1003359.
- 624 17. Vasquez M, Zuniga M, Rodriguez A. Oxidative Stress and Pathogenesis in Malaria. Front  
625 Cell Infect Microbiol. 2021;11.
- 626 18. Van Avondt K, Nur E, Zeerleder S. Mechanisms of haemolysis-induced kidney injury. Nat  
627 Rev Nephrol. 2019;15(11):671-92.
- 628 19. Elphinstone RE, Conroy AL, Hawkes M, Hermann L, Namasopo S, Warren HS, et al.  
629 Alterations in Systemic Extracellular Heme and Hemopexin Are Associated With Adverse  
630 Clinical Outcomes in Ugandan Children With Severe Malaria. J Infect Dis.  
631 2016;214(8):1268-75.
- 632 20. Belachew EB. Immune Response and Evasion Mechanisms of Plasmodium falciparum  
633 Parasites. J Immunol Res. 2018;2018:6529681.
- 634 21. Gomes PS, Bhardwaj J, Rivera-Correa J, Freire-De-Lima CG, Morrot A. Immune Escape  
635 Strategies of Malaria Parasites. Front Microbiol. 2016;7.
- 636 22. Plewes K, Royakkers AA, Hanson J, Hasan MM, Alam S, Ghose A, et al. Correlation of  
637 biomarkers for parasite burden and immune activation with acute kidney injury in severe  
638 falciparum malaria. Malar J. 2014;13:91.
- 639 23. Nguansangiam S, Day NP, Hien TT, Mai NT, Chaisri U, Riganti M, et al. A quantitative  
640 ultrastructural study of renal pathology in fatal Plasmodium falciparum malaria. Trop Med Int  
641 Health. 2007;12(9):1037-50.
- 642 24. Nayak KC, Kumar S, Gupta BK, Kumar S, Gupta A, Prakash P, et al. Clinical and  
643 histopathological profile of acute renal failure caused by falciparum and vivax

- 644 monoinfection: an observational study from Bikaner, northwest zone of Rajasthan, India. J  
645 Vector Borne Dis. 2014;51(1):40-6.
- 646 25. Souza MC, Padua TA, Henriques MG. Endothelial-Leukocyte Interaction in Severe  
647 Malaria: Beyond the Brain. Mediators Inflamm. 2015;2015:168937.
- 648 26. Ouma BJ, Ssenkusu JM, Shabani E, Datta D, Opoka RO, Idro R, et al. Endothelial  
649 Activation, Acute Kidney Injury, and Cognitive Impairment in Pediatric Severe Malaria. Crit  
650 Care Med. 2020;48(9):e734-e43.
- 651 27. Hanson J, Lee SJ, Hossain MA, Anstey NM, Charunwatthana P, Maude RJ, et al.  
652 Microvascular obstruction and endothelial activation are independently associated with the  
653 clinical manifestations of severe falciparum malaria in adults: an observational study. BMC  
654 Med. 2015;13:122.
- 655 28. Ortega-Pajares A, Rogerson SJ. The Rough Guide to Monocytes in Malaria Infection.  
656 Front Immunol. 2018;9:2888.
- 657 29. Hawkes MT, Leligdowicz A, Batte A, Situma G, Zhong K, Namasopo S, et al.  
658 Pathophysiology of Acute Kidney Injury in Malaria and Non-Malarial Febrile Illness: A  
659 Prospective Cohort Study. Pathog. 2022;11(4):436.
- 660 30. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, et al.  
661 Whole blood angiopoietin-1 and-2 levels discriminate cerebral and severe (non-cerebral)  
662 malaria from uncomplicated malaria. Malar J. 2009;8(1):1-7.
- 663 31. Jaber BL, Liangos O, Pereira BJG, Balakrishnan VS. Polymorphism of  
664 Immunomodulatory Cytokine Genes: Implications in Acute Renal Failure. Blood Purific.  
665 2004;22(1):101-11.

- 666 32. Jaber BL, Pereira BJ, Bonventre JV, Balakrishnan VS. Polymorphism of host response  
667 genes: implications in the pathogenesis and treatment of acute renal failure. *Kidney Int.*  
668 2005;67(1):14-33.
- 669 33. Hill AV. The immunogenetics of resistance to malaria. *Proc Assoc Am Physicians.*  
670 1999;111(4):272-7.
- 671 34. Penha-Gonçalves C. Genetics of Malaria Inflammatory Responses: A Pathogenesis  
672 Perspective. *Front Immunol.* 2019;10:1771.
- 673 35. Driss A, Hibbert JM, Wilson NO, Iqbal SA, Adamkiewicz TV, Stiles JK. Genetic  
674 polymorphisms linked to susceptibility to malaria. *Malar J.* 2011;10:271.
- 675 36. Dhangadamajhi G, Kar A, Rout R, Dhangadamajhi P. A meta-analysis of TLR4 and TLR9  
676 SNPs implicated in severe malaria. *Rev Soc Bras Med Trop.* 2017;50(2):153-60.
- 677 37. Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, et al. Soluble  
678 Urokinase Receptor and Acute Kidney Injury. *N Engl J Med.* 2020;382(5):416-26.
- 679 38. Griffin BR, Gist KM, Faubel S. Current Status of Novel Biomarkers for the Diagnosis of  
680 Acute Kidney Injury: A Historical Perspective. *J Intensive Care Med.* 2020;35(5):415-24.
- 681 39. Basu RK, Zappitelli M, Brunner L, Wang Y, Wong HR, Chawla LS, et al. Derivation and  
682 validation of the renal angina index to improve the prediction of acute kidney injury in  
683 critically ill children. *Kidney Int.* 2014;85(3):659-67.
- 684 40. Health ZMo. Zambia Malaria Indicator Survey.: Government of the Republic of Zambia,  
685 Ministry of Health; 2021.
- 686 41. Moussiliou A, Alao MJ, Denoed-Ndam L, Tahar R, Ezimegnon S, Sagbo G, et al. High  
687 Plasma Levels of Soluble Endothelial Protein C Receptor Are Associated With Increased  
688 Mortality Among Children With Cerebral Malaria in Benin. *J Infect Dis.* 2014;211(9):1484-8.



- 689 42. Gwer S, Newton CR, Berkley JA. Over-diagnosis and co-morbidity of severe malaria in  
690 African children: a guide for clinicians. *Am J Trop Med Hyg.* 2007;77(6 Suppl):6-13.
- 691 43. Severe malaria. *Trop Med Int Health.* 2014;19 Suppl 1:7-131.
- 692 44. Oshomah-Bello EO, Esezobor CI, Solarin AU, Njokanma FO. Acute Kidney Injury in  
693 Children with Severe Malaria Is Common and Associated with Adverse Hospital Outcomes. *J*  
694 *Trop Pediatr.* 2020;66(2):218-25.
- 695 45. Narsaria N, Mohanty C, Das BK, Mishra SP, Prasad R. Oxidative stress in children with  
696 severe malaria. *J Trop Pediatr.* 2012;58(2):147-50.
- 697 46. Nagamine Y, Hayano M, Kashiwamura S-i, Okamura H, Nakanishi K, Krudsod S, et al.  
698 Involvement of interleukin-18 in severe *Plasmodium falciparum* malaria. *Trans R Soc Trop*  
699 *Med Hyg.* 2003;97(2):236-41.
- 700 47. Elhussein AB, Huneif MA, Naeem A, Fadleseed OE, Babiker WG, Rahma NE, et al.  
701 Correlation of interleukin-4 levels with *Plasmodium falciparum* malaria parasitaemia in  
702 Sudanese children. *Acta Clin Belg.* 2015;70(6):414-8.
- 703 48. Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, Banchereau J. High levels of  
704 circulating IL-10 in human malaria. *Clin Exp Immunol.* 1994;95(2):300-3.
- 705 49. Lyke K, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, et al. Serum levels of the  
706 proinflammatory cytokines interleukin-1 beta (IL-1 $\beta$ ), IL-6, IL-8, IL-10, tumor necrosis  
707 factor alpha, and IL-12 (p70) in Malian children with severe *Plasmodium falciparum* malaria  
708 and matched uncomplicated malaria or healthy controls. *Infect immun.* 2004;72(10):5630-7.
- 709 50. Kwiatkowski D, Sambou I, Twumasi P, Greenwood B, Hill A, Manogue K, et al. TNF  
710 concentration in fatal cerebral, non-fatal cerebral, and uncomplicated *Plasmodium falciparum*  
711 malaria. *The Lancet.* 1990;336(8725):1201-4.

- 712 51. Chaiyaroj SC, Rutta AS, Muenthaisong K, Watkins P, Na Ubol M, Looareesuwan S.  
713 Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration  
714 inhibitory factor are associated with severe malaria. *Acta Trop.* 2004;89(3):319-27.
- 715 52. Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, et al.  
716 Serum angiopoietin-1 and-2 levels discriminate cerebral malaria from uncomplicated malaria  
717 and predict clinical outcome in African children. *PloS one.* 2009;4(3):e4912.
- 718 53. Howie SR. Blood sample volumes in child health research: review of safe limits. *Bull*  
719 *World Health Organ.* 2011;89(1):46-53.
- 720 54. Zambia MoHo. Dried Blood Spot for DNA PCCR Testing. 1 ed. Lusaka: Ministry of  
721 Health; 2007.
- 722 55. Organization WH. The treatment of diarrhoea: a manual for physicians and other senior  
723 health workers. World Health Organization; 2005. Report No.: 9241593180.
- 724 56. Selewski DT, Cornell TT, Lombel RM, Blatt NB, Han YY, Mottes T, et al. Weight-based  
725 determination of fluid overload status and mortality in pediatric intensive care unit patients  
726 requiring continuous renal replacement therapy. *Intensive Care Med.* 2011;37(7):1166-73.
- 727 57. Matsuura R, Srisawat N, Claire-Del Granado R, Doi K, Yoshida T, Nangaku M, et al. Use  
728 of the Renal Angina Index in Determining Acute Kidney Injury. *Kidney Int Rep.*  
729 2018;3(3):677-83.
- 730 58. Matsuura R, Iwagami M, Moriya H, Ohtake T, Hamasaki Y, Nangaku M, et al. A Simple  
731 Scoring Method for Predicting the Low Risk of Persistent Acute Kidney Injury in Critically  
732 Ill Adult Patients. *Sci Rep.* 2020;10(1):5726.

733 59. Zulu C, Mwaba C, Wa Somwe S. The renal angina index accurately predicts low risk of  
734 developing severe acute kidney injury among children admitted to a low-resource pediatric  
735 intensive care unit. *Ren Fail.* 2023;45(2):2252095.

736

737 **Supporting information**  
738 **S1 effect sizes and estimation of sample size**  
739 **S2 List of primer sequences**